Cargando…

Screening for participants in the ISCHEMIA trial: Implications for clinical research

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) found that there was no statistical difference in cardiovascular events with an initial invasive strategy as compared with an initial conservative strategy of guideline-directed medical therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Fatima, Hochman, Judith S., Xu, Yifan, Reynolds, Harmony R., Berger, Jeffrey S., Mavromichalis, Stavroula, Newman, Jonathan D., Bangalore, Sripal, Maron, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389278/
https://www.ncbi.nlm.nih.gov/pubmed/36003207
http://dx.doi.org/10.1017/cts.2022.428
_version_ 1784770408514322432
author Rodriguez, Fatima
Hochman, Judith S.
Xu, Yifan
Reynolds, Harmony R.
Berger, Jeffrey S.
Mavromichalis, Stavroula
Newman, Jonathan D.
Bangalore, Sripal
Maron, David J.
author_facet Rodriguez, Fatima
Hochman, Judith S.
Xu, Yifan
Reynolds, Harmony R.
Berger, Jeffrey S.
Mavromichalis, Stavroula
Newman, Jonathan D.
Bangalore, Sripal
Maron, David J.
author_sort Rodriguez, Fatima
collection PubMed
description The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) found that there was no statistical difference in cardiovascular events with an initial invasive strategy as compared with an initial conservative strategy of guideline-directed medical therapy for patients with moderate to severe ischemia on noninvasive testing. In this study, we describe the reasons that potentially eligible patients who were screened for participation in the ISCHEMIA trial did not advance to enrollment, the step prior to randomization. Of those who preliminarily met clinical inclusion criteria on screening logs submitted during the enrollment period, over half did not participate due to physician or patient refusal, a potentially modifiable barrier. This analysis highlights the importance of physician equipoise when advising patients about participation in randomized controlled trials.
format Online
Article
Text
id pubmed-9389278
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-93892782022-08-23 Screening for participants in the ISCHEMIA trial: Implications for clinical research Rodriguez, Fatima Hochman, Judith S. Xu, Yifan Reynolds, Harmony R. Berger, Jeffrey S. Mavromichalis, Stavroula Newman, Jonathan D. Bangalore, Sripal Maron, David J. J Clin Transl Sci Brief Report The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) found that there was no statistical difference in cardiovascular events with an initial invasive strategy as compared with an initial conservative strategy of guideline-directed medical therapy for patients with moderate to severe ischemia on noninvasive testing. In this study, we describe the reasons that potentially eligible patients who were screened for participation in the ISCHEMIA trial did not advance to enrollment, the step prior to randomization. Of those who preliminarily met clinical inclusion criteria on screening logs submitted during the enrollment period, over half did not participate due to physician or patient refusal, a potentially modifiable barrier. This analysis highlights the importance of physician equipoise when advising patients about participation in randomized controlled trials. Cambridge University Press 2022-07-13 /pmc/articles/PMC9389278/ /pubmed/36003207 http://dx.doi.org/10.1017/cts.2022.428 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Rodriguez, Fatima
Hochman, Judith S.
Xu, Yifan
Reynolds, Harmony R.
Berger, Jeffrey S.
Mavromichalis, Stavroula
Newman, Jonathan D.
Bangalore, Sripal
Maron, David J.
Screening for participants in the ISCHEMIA trial: Implications for clinical research
title Screening for participants in the ISCHEMIA trial: Implications for clinical research
title_full Screening for participants in the ISCHEMIA trial: Implications for clinical research
title_fullStr Screening for participants in the ISCHEMIA trial: Implications for clinical research
title_full_unstemmed Screening for participants in the ISCHEMIA trial: Implications for clinical research
title_short Screening for participants in the ISCHEMIA trial: Implications for clinical research
title_sort screening for participants in the ischemia trial: implications for clinical research
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389278/
https://www.ncbi.nlm.nih.gov/pubmed/36003207
http://dx.doi.org/10.1017/cts.2022.428
work_keys_str_mv AT rodriguezfatima screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT hochmanjudiths screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT xuyifan screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT reynoldsharmonyr screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT bergerjeffreys screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT mavromichalisstavroula screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT newmanjonathand screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT bangaloresripal screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch
AT marondavidj screeningforparticipantsintheischemiatrialimplicationsforclinicalresearch